相关实验视频

Updated: May 5, 2026

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

从美国诊所5年佩格瓦里亚酶的经验中吸取的教训:一个案例系列

Erin Cooney¹, Zineb Ammous², Tricia Bender³

¹University of Texas Medical Branch, Galveston, TX, USA.

Molecular genetics and metabolism reports

|January 16, 2025

概括

在基尿症 (PKU) 中,pegvaliase (pegvaliase) 管理甚至可以在复杂的情况下取得成功. 策略应对并发症和坚持等挑战,改善PKU症状.

科学领域:

生物化学生物化学
遗传学遗传学是一个
代谢障碍代谢障碍代谢障碍

背景情况:

基尿 (PKU) 是一种罕见的遗传疾病,需要终身治疗.
在PKU中氨 (Phe) 水平升高可能导致严重的神经损伤.
佩格瓦里亚斯 (Pegvaliase) 通过降低血液中的Phe水平,为PKU提供一种治疗选择.

研究的目的:

为在具有挑战性的基尿症 (PKU) 病例中管理基酶提供见解和策略.
为了分享从5年的真实世界临床实践中学到的经验教训 pegvaliase.
为了指导医疗保健专业人员在治疗复杂的成年PKU病例用pegvaliase.

主要方法:

十二名PKU专家的共识会议举行.
讨论了临床案例,说明了 pegvaliase 治疗中的挑战和策略.
审查了成年PKU患者对佩格瓦里酶的现实经验.

主要成果:

在大多数复杂的PKU病例中,尽管存在并发症,执行功能缺陷或社会经济挑战,但Pegvaliase启动成功.
策略包括个性化教育,支持组织,远程医疗和与当地提供者合作.
建议密切监测并发病症,并通过提醒或修改计划解决遵守问题.
降低血液Phe水平导致PKU相关症状改善,包括神经问题.

结论:

在患有PKU的成年人中,即使在具有各种障碍的复杂病例中,Pegvaliase治疗也可以取得成功.
综合评估和量身定制的策略是克服治疗挑战的关键.
对临床经验的持续记录对于在PKU中推进佩格瓦里亚酶管理至关重要.

关键词:

案件系列案件系列专家意见专家意见在PKU中,PKU是PKU.佩格瓦里亚斯 (Pegvaliase) 是一个基尿症基尿症治疗方法治疗方法

更多相关视频

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

相关概念视频

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...